Back to search
Myotonic Dystrophy Type 1 (DM1)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Myotonic Dystrophy Type 1 (DM1) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Myotonic Dystrophy Type 1 (DM1) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics…
This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic…
Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy. It is characte…
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1)…
The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PG…
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different co…
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy T…
This natural history observational study is being conducted to follow patients with DM1 or DM2 over a 2 year period to study the presence of myotonia, how it's…